cnbc.com / .cnbc-com-health-care

We're cutting loose the smallest position in our portfolio.

Europe's pharmaceutical sector is bracing for the potential impact of U.S. tariffs as hopes of an industry-wide exemption by President Donald Trump fade.

Hims & Hers is adding Zepbound, Mounjaro, and the generic injection liraglutide to its platform.

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

The drug stock is higher over the past month while the S&P 500 has pulled back sharply.

Shares of Moderna, Novavax and other biotech companies fell after FDA official Peter Marks's resignation in protest of Robert F. Kennedy Jr.

Genetic testing company 23andMe's bankruptcy has led to a new consumer privacy issue: what happens to the DNA of millions of Americans when it goes on sale?

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.

The Food and Drug Administration's top vaccine regulator Peter Marks has resigned, citing Sec. Robert F. Kennedy Jr.'s "misinformation and lies" around immunization.